Address
One Broadway
Cambridge, MA 02142
United States of America (the)
Phone
857 357 7000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
162
First IPO Date
July 29, 2021
| Name | Title | Pay | Year Born |
| James R. Porter | Chief Executive Officer, President & Director | 1.14M | 1976 |
| Deborah Ann Miller | Chief Legal Officer & Secretary | 740,701 | 1976 |
| Darlene Noci | Chief Development Officer | 741,317 | 1978 |
| Alex Balcom | Chief Financial Officer & Treasurer | 753,791 | 1984 |
| Christopher D. Turner | Chief Medical Officer | 822,475 | 1969 |
| Henry Pelish | Chief Scientific Officer | 0 | 1973 |
| Chelcie Lister | Senior Director of Investor Relations & Corporate Communications | 0 | N/A |
| Benjamin Lane | Chief Technical Operations Officer | 0 | N/A |
| John Soglia | Senior Vice President of Translational Development | 0 | N/A |
| Joshua Horan | Senior Vice President of Chemistry | 0 | N/A |
| Matthew Metivier | Senior Vice President of Human Resources | 0 | N/A |
| Ruth Adams | Senior Vice President of Clinical Operations | 0 | N/A |
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.